Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report

Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report

Abstract Background Currently, immune checkpoint (ICP) inhibitors are essential drugs for the treatment of non-small cell lung cancer (NSCLC). However, in patients previously treated with ICP inhibitors, the efficacy and safety of re-challenging the same or another ICP inhibitor remain unclear. Case...

Full description

Bibliographic Details
Main Authors: Taiki Hakozaki, Yusuke Okuma, Jumpei Kashima
Format: Article
Language:English
Published: BMC 2018-03-01
Series:BMC Cancer
Subjects:
Nivolumab
Immune checkpoint inhibitor
Non-small cell lung cancer
Immune-related adverse events
Re-challenge
Online Access:http://link.springer.com/article/10.1186/s12885-018-4212-1

Internet

http://link.springer.com/article/10.1186/s12885-018-4212-1

Similar Items